In a type 1 diabetes mouse model, apelin-13 treatment reduced glomerular hypertrophy and mesangial matrix deposition, decreased albuminuria, and delayed renal inflammation [25]. This evidence concerns the gene APLN and type 1 diabetes mellitus.